- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06272695
Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes. After informed consent, Screening procedures to establish subject eligibility will be performed within a period of 28 days. Approximately 24 subjects with type 1 diabetes mellitus (T1DM) on stable doses of insulin will be enrolled.
After enrollment, subjects will undergo a baseline Hypoglycemia Recovery Procedure (with glucagon rescue). Subjects will then receive volagidemab subcutaneously (SC) once weekly for 6 weeks. At the end of the treatment phase, subjects will undergo a second Hypoglycemia Recovery Procedure. Subjects will be followed for 6 weeks after the last volagidemab dose with a final End-of-Study (EOS) visit during Week 12. The primary outcome will be the change in time to glucagon treatment success at Week 6 versus baseline.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Zung Thai, MD
- Phone Number: 415-225-9338
- Email: zungthai@remdbio.com
Study Contact Backup
- Name: Edgar Bautista
- Email: edgarbautista@remdbio.com
Study Locations
-
-
California
-
San Diego, California, United States, 92037
- Not yet recruiting
- Altman Clinical and Translational Research Institute
-
Contact:
- Schafer Boeder, MD
-
Principal Investigator:
- Schafer Baoder, MD
-
Walnut Creek, California, United States, 94598
- Recruiting
- Diablo Clinical Research
-
Contact:
- Mark Christiansen, MD
- Email: mchristiansen@diabloclinical.com
-
Principal Investigator:
- Mark Christiansen, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Receiving insulin for the treatment of documented diagnosis of T1DM for at least 2 years
- Body Mass Index (BMI) of 18.5 kg/m2 to 35.0 kg/m2
- On treatment with a stable insulin regimen for at least 8 weeks
- Currently using a continuous glucose monitoring (CGM) system
- HbA1c less than or equal to 10.0%
- Females of non-childbearing potential must be ≥1 year post-menopausal or documented as being surgically sterile. Females of childbearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product
- Male subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 3 months after the end of the treatment period
- Other inclusion criteria may apply.
Exclusion Criteria:
- History of type 2 diabetes, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
- Pancreas, pancreatic islet cells, or renal transplant recipient
- T1DM treatment with any other antihyperglycemic drug (e.g., metformin, alpha- glucosidase inhibitors, SGLT-2 inhibitors, pramlintide, inhaled insulin, pre-mixed insulins, etc.) within 30 days of Day 1
- Occurrence of severe hypoglycemia involving coma and/or seizure that required hospitalization or hypoglycemia-related treatment by an emergency physician or paramedic within 3 months prior to Day 1
- Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident ≤12 weeks
- Indication of liver disease
- Current signs and symptoms of anemia
- Untreated eating disorders such as bulimia or anorexia nervosa
- History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia (MEN) or family history of MEN.
- Treatment with systemic corticosteroids within 30 days of Day 1, or planned initiation of such therapy during the study.
- Medical history of cancer or treatment for cancer in the last five years
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Other exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 35 mg Volagidemab
Volagidemab 35 mg will be administered by subcutaneous (SC) injection once weekly for 6 weeks.
|
Administered by SC injection once weekly for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Time to glucagon treatment success at Week 6.
Time Frame: 6 weeks
|
The primary outcome of the study is the change in time to glucagon treatment success, defined as an increase in plasma glucose of ≥20 mg/dL from the glucose nadir after receiving glucagon during insulin-induced hypoglycemia, from baseline to Week 6.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood glucose response to glucagon rescue treatment during insulin-induced hypoglycemia.
Time Frame: 6 weeks
|
Percentage of subjects achieving glucagon treatment success, defined as an increase in plasma glucose to ≥70 mg/dL or an increase of ≥20 mg/dL from the glucose nadir within 30 minutes of receiving glucagon during insulin-induced hypoglycemia, at Week 6.
|
6 weeks
|
Treatment emergent adverse events (AEs)
Time Frame: 12 weeks
|
The subject incidence rates of AEs will be tabulated by system organ class, preferred term, and severity grade for all treatment emergent, serious, treatment related, and serious treatment related AEs.
|
12 weeks
|
Hypoglycemia symptoms - Edinburgh Hypoglycemia Scale
Time Frame: 6 weeks
|
Results of the Edinburgh Hypoglycemia Scale will be summarized over Intent-to-Treat (ITT) set using descriptive statistics by visit (baseline, week 6) and timepoint (baseline, t = 15, 30, 45, and 60 min after glucagon administration for Edinburgh Hypoglycemia Scale).
Changes from baseline in Edinburgh hypoglycemia scale will be summarized similarly.
|
6 weeks
|
Hypoglycemia symptoms - Clarke Survey
Time Frame: 6 weeks
|
Results of the Clarke Survey will be summarized over Intent-to-Treat (ITT) set using descriptive statistics by visit (baseline, week 6).
Changes from baseline in Clarke Survey will be summarized similarly.
|
6 weeks
|
Hypoglycemia symptoms - Gold Questionnaire
Time Frame: 6 weeks
|
Results of the Gold Questionnaire will be summarized over Intent-to-Treat (ITT) set using descriptive statistics by visit (baseline, week 6).
Changes from baseline in Gold Questionnaire will be summarized similarly.
|
6 weeks
|
Change from baseline in hemoglobin A1c (HbA1c) at Week 6.
Time Frame: 6 weeks
|
Change from baseline in hemoglobin A1c (HbA1c) at Week 6, after repeated doses of volagidemab
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Zung Thai, MD, REMD Biotherapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R477-203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Volagidemab
-
REMD Biotherapeutics, Inc.CompletedDiabetes | Type 2 Diabetes MellitusUnited States
-
REMD Biotherapeutics, Inc.CompletedType1 Diabetes MellitusUnited States
-
REMD Biotherapeutics, Inc.CompletedDiabetes | Type 1 Diabetes MellitusUnited States
-
Duke UniversityTerminatedHyperglycemia Drug InducedUnited States
-
Duke UniversityTerminatedHyperglycemia Drug InducedUnited States
-
University of California, San DiegoREMD Biotherapeutics, Inc.Completed
-
The University of Texas Health Science Center at...SuspendedType 2 Diabetes | Insulin Sensitivity | Glucose Tolerance ImpairedUnited States
-
University of California, San DiegoREMD Biotherapeutics, Inc.Active, not recruiting
-
University of California, San DiegoJuvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaboratorsCompleted
-
University of California, San DiegoJuvenile Diabetes Research FoundationNot yet recruiting